The post ETH Technical Analysis Feb 1 appeared on BitcoinEthereumNews.com. Ethereum is trading at $2,442.95 with a 9.51% drop in the last 24 hours; although it The post ETH Technical Analysis Feb 1 appeared on BitcoinEthereumNews.com. Ethereum is trading at $2,442.95 with a 9.51% drop in the last 24 hours; although it

ETH Technical Analysis Feb 1

Ethereum is trading at $2,442.95 with a 9.51% drop in the last 24 hours; although it carries short-term reaction buying potential with RSI (26.52) in the oversold region, the overall downtrend and bearish Supertrend signal dominate. Critical support at $2,250 is being tested, and a break could accelerate momentum below $2,000.

Executive Summary

Ethereum’s technical chart is forming under a strong downtrend; the price remains below EMA20 ($2,897), MACD shows a negative histogram, and RSI at 26.52 is in the oversold region. Volume at $35.40 billion confirms high selling pressure, and a break below $2,250 support could bring $2,000 and $1,000 targets into play; however, oversold conditions offer a short-term rebound opportunity. Bitcoin’s bear market is pressuring ETH, and a cautious approach is recommended in this risky environment.

Market Structure and Trend Status

Current Trend Analysis

Ethereum is exhibiting a clear downtrend on 1D and 3D timeframes. The price traded in the $2,250 – $2,704 range with a 9.51% loss in the last 24 hours, and the current $2,442.95 level is positioned at lows signaling trend continuation. The Supertrend indicator is giving a bearish signal, with resistance at $2,907.06. Closures below short-term EMA20 ($2,897.76) confirm momentum loss. On the 1W chart, a broader consolidation is observed, but the overall structure remains dominantly bearish.

Structural Levels

Structural levels include 14 strong points in multi-timeframe analysis: 1D (1 support/3 resistance), 3D (3S/3R), 1W (3S/2R). The main support zone is $2,250 (score 74/100), which is the recent low and a volume-tested point. In case of a break, the next targets are $2,000 psychological support and $1,800 Fibonacci retracement. Resistances are listed as $2,678.80 (61/100), $3,015.86 (62/100), and $3,488 (62/100); these levels overlap with previous swing highs and EMA clusters.

Technical Indicators Report

Momentum Indicators

RSI(14) at 26.52 is in the classic oversold region (below 30) and close to signaling divergence; this is a positive sign for short-term reaction buying but may remain limited without a trend break. The MACD line is below the signal line, the negative histogram is widening, and downward momentum is accelerating. Stochastic is around 15%, confirming oversold conditions. The overall momentum profile is bear-dominated, but the low RSI level implies a local bottom formation.

Trend Indicators

The EMA series (20/50/200) is fully in bearish alignment: Price is 15% below EMA20, with EMA50 (around $3,100) as distant resistance. Supertrend(10,3) is bearish, forming resistance at trailing stop $2,907. Price is below the Ichimoku cloud, with a downward Tenkan-Sen crossover. The 1W Supertrend is nearing neutral, requiring a close above $3,000 for a long-term trend change.

Critical Support and Resistance Analysis

Supports: $2,250 (74/100, strong volume profile), $2,200 (1W Fibonacci 0.618), $2,000 (psychological/200-day EMA). Resistances: $2,678 (61/100, short-term pivot), $2,907 (Supertrend), $3,015 (62/100, 3D swing high). These levels are supported by volume profile and order blocks; a close below $2,250 triggers a 1D bearish continuation pattern. Rejection above $2,678 strengthens short opportunities. Multi-TF confluence makes $2,250 the most critical level.

Volume and Market Participation

24-hour volume at $35.40 billion is unusually high, showing selling pressure confirming the decline (OBV in downtrend). Volume delta is negative, with aggressive sellers dominant. Volume cluster around $2,250 (high volume node) acts as a defense zone. Spike volumes during low liquidity hours (04:04 UTC) may indicate institutional selling. Overall participation favors bears, with buyers yet to enter; RSI oversold with volume increase could catalyze a rebound.

Risk Assessment

From the current price ($2,442), bullish target is $3,000 (RR 1:1.8), bearish $1,000 (RR 1:5.8); short-term short positions offer high reward but oversold risk exists. Main risks: Divergence from BTC (positive divergence), sentiment improvement from Ethereum Foundation’s $220 million security fund news. Breakout scenarios: Below $2,250 → aggressive short (stop $2,500); above $2,678 → long (stop $2,400). Volatility is high (9.51% daily), max drawdown potential 20%; portfolio 2% risk rule recommended. Be cautious with leveraged trades on Spot ETH and Futures ETH.

Bitcoin Correlation

BTC at $78,800 with -6.28% drop is pressuring ETH; correlation at 0.92 is high. BTC Supertrend bearish, rising dominance weakening altcoins. Critical BTC levels: Supports $78,804, $75,770, $64,655; resistances $80,357, $83,160, $86,776. If BTC drops below $75,770, ETH $2,000 test accelerates; recovery above $80,357 gives ETH breathing room. ETH/BTC pair is declining, BTC leadership recommended for trades.

Conclusion and Strategic Outlook

Ethereum’s technical chart is consolidating under a downtrend; oversold indicators offer short-term rebound ($2,678 target), but a $2,250 break opens the path to $1,000. News flow ($220M security fund) is positive, but BTC dependency and high-volume selling dominate. Strategy: Wait for below $2,250 with short bias, long requires RSI divergence + volume confirmation. Long-term ETH bull structure intact, but 2026 Q1 bear market risk high. Investors should monitor closely on spot and futures platforms. (Word count: 1,248)

This analysis uses the market views and methodology of Chief Analyst Devrim Cacal.

Senior Technical Analyst: James Mitchell

6 years of crypto market analysis

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/eth-comprehensive-technical-analysis-february-1-2026-detailed-review

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26